Home
>
National Drug Code (NDC)
>
XOLAIR
XOLAIR - 50242-040-62 - (omalizumab)
Drug Information of XOLAIR
| Product NDC: | 50242-040 |
| Proprietary Name: | XOLAIR |
| Non Proprietary Name: | omalizumab |
| Active Ingredient(s): | 202.5 mg/1.4mL & nbsp; omalizumab |
| Administration Route(s): | SUBCUTANEOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of XOLAIR
| Product NDC: | 50242-040 |
| Labeler Name: | Genentech, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA103976 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20030620 |
Package Information of XOLAIR
| Package NDC: | 50242-040-62 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-040-62) > 1.4 mL in 1 VIAL, SINGLE-USE |
NDC Information of XOLAIR
| NDC Code | 50242-040-62 |
| Proprietary Name | XOLAIR |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-040-62) > 1.4 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 50242-040 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | omalizumab |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | SUBCUTANEOUS |
| Start Marketing Date | 20030620 |
| Marketing Category Name | BLA |
| Labeler Name | Genentech, Inc. |
| Substance Name | OMALIZUMAB |
| Strength Number | 202.5 |
| Strength Unit | mg/1.4mL |
| Pharmaceutical Classes | Anti-IgE [EPC],Decreased IgE Activity [PE],IgE-directed Antibody Interactions [MoA] |
